Results 41 to 50 of about 482,699 (357)
Journal for ImmunoTherapy of Cancer, 2017 Background Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogeneity has not been extensively ...
Sotirios P. Fortis +11 more
doaj +1 more source
Identification and validation of targets for cancer immunotherapy: from the bench-to-bedside [PDF]
, 2013 Chapter 12 in Novel Gene Therapy ...
Brooks, Suzanne E. +4 more
core +2 more sources
Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients. [PDF]
, 2020 Chemotherapy and checkpoint inhibitor immunotherapies are increasingly used in combinations. We determined associations between the presence of anti-PD-1/PD-L1 therapeutic biomarkers and protein markers of potential chemotherapy response.
Arguello, David +5 more
core +2 more sources
Cancer Immunology and Immunotherapy [PDF]
BioMed Research International, 2015 The study of molecular and cellular interplays between immune system and cancerous cells is gaining tremendous momentum across the globe. Concomitantly, with the better insight into the intricacies of cancer immunology, immunotherapeutic approaches to deal with cancer have garnered tremendous boost in the recent past; reckoning with these, it is timely
Mohammad Owais +3 more
openaire +4 more sources
TIGIT in cancer immunotherapy [PDF]
Journal for ImmunoTherapy of Cancer, 2020 Tumors evade immune-mediated recognition through multiple mechanisms of immune escape. On chronic tumor antigen exposure, T cells become dysfunctional/exhausted and upregulate various checkpoint inhibitory receptors (IRs) that limit T cells’ survival and function.
Joe-Marc Chauvin, Hassane M. Zarour
openaire +3 more sources
Nature Communications, 2023 Efficacy of cancer vaccines remains low and mechanistic understanding of antigen presenting cell function in cancer may improve vaccine design and outcomes.
Juraj Adamik +6 more
doaj +1 more source
Optimal chemotherapy and immunotherapy schedules for a cancer-obesity model with Caputo time fractional derivative [PDF]
, 2018 This work presents a new mathematical model to depict the effect of obesity on cancerous tumor growth when chemotherapy as well as immunotherapy have been administered. We consider an optimal control problem to destroy the tumor population and minimize the drug dose over a finite time interval.
arxiv +1 more source
Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. [PDF]
, 2018 Peritoneal metastasis (PM) is an advanced stage malignancy largely refractory to modern therapy. Intraperitoneal (IP) immunotherapy offers a novel approach for the control of regional disease of the peritoneal cavity by breaking immune tolerance.
Bowne, Wilbur B. +5 more
core +2 more sources
Journal for ImmunoTherapy of Cancer, 2019 Background Cancer immunotherapies are emerging as promising treatment strategies for ovarian cancer patients that experience disease relapse following first line therapy.
A. J. Robert McGray +11 more
doaj +1 more source
, 2011 Much of our knowledge regarding cancer immunotherapy has been derived from sarcoma models. However, translation of preclinical findings to bedside success has been limited in this disease, though several intriguing clinical studies hint at the potential ...
Gouw, Launce G +3 more
core +2 more sources